Skip to main content
Over fifteen thousand published articles. Over seven hundred and forty clinical trials. Over 5 million packs distributed.

GLEEVEC is supported by clinical trial data backed by more than two decades of clinical use.1 First approved by the US Food and Drug Administration in 2001,1 the figures speak for themselves:

  • Over 15,000 published articles2

  • Over 740 clinical trials3

  • Over 5,000,000 packs distributed4

GLEEVEC has a well-established safety profile.

Thank you for trusting in GLEEVEC.

 

GLEEVEC BLISTER PACKAGING INSTRUCTIONAL VIDEO

SHELLPAK is a registered trademark of Westrock MWV, LLC. 

Novartis. Universal Co-Pay Card.

UNIVERSAL CO-PAY PROGRAM

Patients may be eligible for immediate co-pay savings on their next prescription of GLEEVEC.

 

  • Eligible patients with private insurance may pay $10 per month

  • Novartis will pay the remaining co-pay, up to $30,000 per calendar year*

 

Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program, or for Massachusetts patients or for California patients that do not meet additional eligibility criteria. Patient pays first $10 co-pay on a 30-day supply, and the program will pay up to $10,630 per 30-day supply up to an annual maximum of $30,000. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.

Patient Assistance Now Oncology Assistance. Access. Answers.

Patient Assistance Now Oncology (PANO)

PANO is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient support programs. Dedicated support specialists help direct callers to the services that best fit their needs. 

 

To learn more, call 1-800-282-7630 or visit Novartis Patient Support.

Important Safety Information

Who Should NOT Take GLEEVEC

  • Women who are or could be pregnant. Harm to the unborn child can occur when administered to a pregnant woman. Therefore, women should not become pregnant and should be advised of the potential risk to the unborn child if GLEEVEC is used during pregnancy. Sexually active females...

Indication

GLEEVEC® (imatinib mesylate) is available only by prescription.

GLEEVEC tablets are indicated for:

  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
References: 
1. Gleevec. Prescribing information. Novartis Pharmaceuticals Corp. 
2. Pubmed. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=gleevec Accessed August 16, 2023. 
3. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/results/map?term=IMATINIB+MESYLATE&map Accessed August 16, 2023. 
4. Data on file. GLEEVEC Packs Distributed (US) From Launch (May 2001-September 2020). Novartis Pharmaceuticals Corp; 2020.